[1]
Ganesan, A. The impact of natural products upon modern drug discovery. Curr. Opin. Chem. Biol., 2008, 12, 306-317.
[2]
Clardy, J.; Walsh, C. Lessons from natural molecules. Nature, 2004, 432, 829-837.
[3]
Song, P.P.; Gao, J.J.; Kokudo, N.; Tang, W. Standardization of traditional Chinese medicine and evaluation of evidence from its clinical practice. Drug Discov. Ther., 2011, 5, 261-265.
[4]
Kennedy, J. Herb and supplement use in the US adult population. Clin. Ther., 2005, 27, 1847-1858.
[5]
Bronstein, A.C.; Spyker, D.A.; Cantilena, L.R., Jr; Green, J.; Rumack, B.H.; Heard, S.E. 2006 annual report of the american association of poison control centers’ National Poison Data System (NPDS). Clin. Toxicol. (Phila.), 2007, 45, 815-917.
[6]
Glisson, J.K.; Walker, L.A. How physicians should evaluate dietary supplements. Am. J. Med., 2010, 123, 577-582.
[7]
Chen, X-W.; Sneed, K.B.; Pan, S.Y.; Cao, C.; Kanwar, J.R.; Chew, H.; Zhou, S-F. Herb-Drug interactions and mechanistic and clinical considerations. Curr. Drug Metab., 2012, 13, 640-6451.
[8]
Werneke, U.; Earl, J.; Seydel, C.; Horn, O.; Crichton, P.; Fannon, D. Potential health risks of complementary alternative medicines in cancer patients. Br. J. Cancer, 2004, 90, 408-413.
[9]
Bunchorntavakul, C.; Reddy, K.R. Review article: Herbal and dietary supplement hepatotoxicity. Aliment. Pharmacol. Ther., 2013, 37, 3-17.
[10]
Aithal, G.P.; Rawlins, M.D.; Day, C.P. Accuracy of hepatic adverse drug reaction reporting in one English health region. BMJ, 1999, 319, 41-45.
[11]
Dalton, H.R. Fellows, H.J: Stableforth, W.; Joseph, M.; Thurairajah, P.H. The role of hepatitis E virus testing in drug-induced liver injury. Aliment. Pharmacol. Ther., 2007, 26, 1429-1435.
[12]
Davern, T.J.; Chalasani, N.; Fontana, R.J.; Hayashi, P.H.; Protiva, P.; Kleiner, D.E.; Engle, R.E.; Nguyen, H.; Emerson, S.U.; Purcell, R.H.; Tillmann, H.L.; Gu, J.; Serrano, J.; Hoofnagle, J.H. Drug-Induced Liver Injury Network (DILIN). Acute hepatitis E infection accounts for some cases of suspected drug-induced liver injury. Gastroenterology, 2011, 141, 1665-1672.
[13]
Teschke, R.; Schulze, J.; Schwarzenboeck, A.; Eickhoff, A.; Frenzel, C. Herbal hepatotoxicity: Suspected cases assessed for alternative causes. Eur. J. Gastroenterol. Hepatol., 2013, 25, 1093-1098.
[14]
Liddle, C.; Goodwin, B. Regulation of hepatic drug metabolism: Role of the nuclear receptors PXR and CAR. Semin. Liver Dis., 2002, 22, 115-122.
[15]
Omura, T. Forty years of cytochrome P450. Biochem. Biophys. Res. Commun., 1999, 266, 690-698.
[16]
Gonzalez, F.J. The molecular biology of cytochrome P450s. Pharmacol. Rev., 1998, 40, 243-288.
[17]
Waxman, D.J.; Azaroff, L. Phenobarbital induction of cytochrome P-450 gene expression. Biochem. J., 1992, 281, 577-592.
[18]
Nelson, D.R.; Kamataki, T.; Waxman, D.J.; Guengerich, F.P.; Estabrook, R.W.; Feyereisen, R.; Gonzalez, F.J.; Coon, M.J.; Gunsalus, I.C.; Gotoh, O. The P450 superfamily: Update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature. DNA Cell Biol., 1993, 12, 1-51.
[19]
Rendic, S.; Di Carlo, F.J. Human cytochrome P450 enzymes: A status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab. Rev., 1997, 29, 413-480.
[20]
Gray, I.C.; Nobile, C.; Muresu, R.; Ford, S.; Spurr, N.K.A. 2.4-megabase physical map spanning the CYP2C gene cluster on chromosome 10q24. Genomics, 1995, 28, 328-332.
[21]
Miners, J.O.; Birkett, D.J. Use of tolbutamide as a substrate probe for human hepatic cytochrome P450 2C9. Methods Enzymol., 1996, 272, 139-145.
[22]
Rettie, A.E.; Korzekwa, K.R.; Kunze, K.L.; Lawrence, R.F.; Eddy, A.C.; Aoyama, T.; Gelboin, H.V.; Gonzalez, F.J.; Trager, W.F. Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: A role for P-4502C9 in the etiology of (S)-warfarin-drug interactions. Chem. Res. Toxicol., 1992, 5, 54-59.
[23]
Henthorn, T.K.; Benitez, J.; Avram, M.J. Assessment of the debrisoquin and dextromethorphan phenotyping tests by gaussian mixture distributions analysis. Clin. Pharmacol. Ther., 1989, 45, 328-333.
[24]
Girre, C.; Lucas, D.; Hispard, E.; Menez, C.; Dally, S.; Menez, J-F. Assessment of cytochrome P4502E1 induction in alcoholic patients by chlorzoxazone pharmacokinetics. Biochem. Pharmacol., 1994, 47, 1503-1508.
[25]
Lieber, C.S. Cytochrome P-4502E1: Its physiological and pathological role. Physiol. Rev., 1997, 77, 517-544.
[26]
Kolars, J.C.; Schmiedlin-Ren, P.; Schuetz, J.D.; Fang, C.; Watkins, P.B. Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. J. Clin. Invest., 1992, 90, 1871-1878.
[27]
Schuetz, E.G.; Guzelian, P.S. Induction of cytochrome P-450 by glucocorticoids in rat liver. II. Evidence that glucocorticoids regulate induction of cytochrome P-450 by a nonclassical receptor mechanism. J. Biol. Chem., 1984, 259, 2007-2012.
[28]
Zhou, S.F.; Lai, X. An update on clinical drug interactions with the herbal antidepressant St. John’s wort. Curr. Drug Metab., 2008, 9, 394-409.
[29]
Harmsen, S.; Meijerman, I.; Beijnen, J.H.; Schellens, J.H. Nuclear receptor mediated induction of cytochrome P450 3A4 by anticancer drugs: A key role for the pregnane X receptor. Cancer Chemother. Pharmacol., 2009, 64, 35-43.
[30]
Quattrochi, L.C.; Guzelian, P.S. Cyp3A regulation: From pharmacology to nuclear receptors. Drug Metab. Dispos., 2001, 29, 615-622.
[31]
Li, Y.; Ross-Viola, J.S.; Shay, N.F.; Moore, D.D.; Ricketts, M.L. Human CYP3A4 and murine Cyp3A11 are regulated by equol and genistein via the pregnane X receptor in a species-specific manner. J. Nutr., 2009, 139, 898-904.
[32]
Al-Dosari, M.S.; Parvez, M.K. Novel plant inducers of PXR-dependent cytochrome P450 3A4 expression in HepG2 cells. Saudi Pharm. J., 2018, 26, 1069-1072.
[33]
Ritter, J.K. Roles of glucuronidation and UDP-glucuronosyl-transferases in xenobiotic bioactivation reactions. Chem. Biol. Interact., 2000, 129, 171-193.
[34]
Radominska-Pandya, A.; Czernik, P.J.; Little, J.M.; Battaglia, E.; Mackenzie, P.I. Structural and functional studies of UDP-glucuronosyltransferases. Drug Metab. Rev., 1999, 31, 817-899.
[35]
Gregory, P.A.; Lewinsky, R.H.; Gardner-Stephen, D.A.; Mackenzie, P.I. Regulation of UDP glucuronosyltransferases in the gastrointestinal tract. Toxicol. Appl. Pharmacol., 2004, 199, 354-363.
[36]
Eraly, S.A.; Bush, K.T.; Sampogna, R.V.; Bhatnagar, V.; Nigam, S.K. The molecular pharmacology of organic anion transporters: from DNA to FDA? Mol. Pharmacol., 2004, 65, 479-487.
[37]
Marchetti, S.; Mazzanti, R.; Beijnen, J.H.; Schellens, J.H. Concise review: Clinical relevance of drug drug and herb drug interactions mediated by the ABC transporter ABCB1 (MDR1, P-glycoprotein). Oncologist, 2004, 12, 927-941.
[38]
Otsuka, M.; Matsumoto, T.; Morimoto, R.; Arioka, S.; Omote, H.; Moriyama, Y. A human transporter protein that mediates the final excretion step for toxic organic cations. Proc. Natl. Acad. Sci. USA, 2005, 102, 17923-17928.
[39]
Aleksunes, L.M.; Cui, Y.; Klaassen, C.D. Prominent expression of xenobiotic efflux transporters in mouse extraembryonic fetal membranes compared with placenta. Drug Metab. Dispos., 2008, 36, 1960-1970.
[40]
Al-Dosari, M.S.; Parvez, M.K. Genetic polymorphisms of drug eliminating enzymes and transporters. Biomed. Genet. Genom., 2016, 1, 44-50.
[41]
Gonzalez, F.J.; Kasper, C.B. Cloning of DNA complementary to rat liver NADPH-cytochrome c (P-450) oxidoreductase and cytochrome P-450b mRNAs. Evidence that phenobarbital augments transcription of specific genes. J. Biol. Chem., 1982, 257, 5962-5968.
[42]
Klotz, U.; Ammon, E. Clinical and toxicological consequences of the inductive potential of ethanol. Eur. J. Clin. Pharmacol., 1998, 54, 7-12.
[43]
Wang, H.; LeCluyse, E.L. Role of orphan nuclear receptors in the regulation of drug-metabolising enzymes. Clin. Pharmacokinet., 2003, 42, 1331-1357.
[44]
Bertilsson, G.; Heidrich, J.; Svensson, K.; Asman, M.; Jendeberg, L.; Sydow-Bäckman, M.; Ohlsson, R.; Postlind, H.; Blomquist, P.; Berkenstam, A. Identification of a human nuclear receptor defines a new signaling pathway for CYP3A induction. Proc. Natl. Acad. Sci. USA, 1998, 95, 12208-12013.
[45]
Lehmann, J.M.; McKee, D.D.; Watson, M.A.; Willson, T.M.; Moore, J.T.; Kliewer, S.A. The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J. Clin. Invest., 1998, 102, 1016-1023.
[46]
Goodwin, B.; Moore, L.B.; Stoltz, C.M.; McKee, D.D.; Kliewer, S.A. Regulation of the human CYP2B6 gene by the nuclear pregnane X receptor. Mol. Pharmacol., 2001, 60, 427-431.
[47]
Gerbal-Chaloin, S.; Pascussi, J.M.; Pichard-Garcia, L.; Daujat, M.; Waechter, F.; Fabre, J.M.; Carrère, N.; Maurel, P. Induction of CYP2C genes in human hepatocytes in primary culture. Drug Metab. Dispos., 2001, 29, 242-251.
[48]
Moore, J.T.; Kliewer, S.A. Use of the nuclear receptor PXR to predict drug interactions. Toxicology, 2000, 153, 1-10.
[49]
Moore, L.B.; Goodwin, B.; Jones, S.A.; Wisely, G.B.; Serabjit-Singh, C.J.; Willson, T.M.; Collins, J.L.; Kliewer, S.A.St. John’s wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc. Natl. Acad. Sci. USA, 2000, 97, 7500-7502.
[50]
Moore, L.B.; Parks, D.J.; Jones, S.A.; Bledsoe, R.K.; Consler, T.G.; Stimmel, J.B.; Goodwin, B.; Liddle, C.; Blanchard, S.G.; Willson, T.M.; Collins, J.L.; Kliewer, S.A. Orphan nuclear receptors constitutive androstane receptor and pregnane X receptor share xenobiotic and steroid ligands. J. Biol. Chem., 2000, 275, 15122-15127.
[51]
Xu, L.W.; Jia, M.; Salchow, R.; Kentsch, M.; Cui, X.J.; Deng, H.Y.; Sun, Z.J.; Kluwe, L. Efficacy and side effects of Chinese herbal medicine for menopausal symptoms: A critical review. Evid. Based Complement. Alternat. Med., 2012, 2012, 568106.
[52]
Hu, D.; Wang, Y.; Chen, Z.; Ma, Z.; You, Q.; Zhang, X.; Liang, Q.; Tan, H.; Xiao, C.; Tang, X.; Gao, Y. The protective effect of piperine on dextran sulfate sodium induced inflammatory bowel disease and its relation with pregnane X receptor activation. J. Ethnopharmacol., 2015, 169, 109-123.
[53]
Hu, D.; Wang, Y.; Chen, Z.; Ma, Z.; You, Q.; Zhang, X.; Zhou, T.; Xiao, Y.; Liang, Q.; Tan, H.; Xiao, C.; Tang, X.; Zhang, B.; Gao, Y. Artemisinin protects against dextran sulfate-sodium-induced inflammatory bowel disease, which is associated with activation of the pregnane X receptor. Eur. J. Pharmacol., 2014, 738, 273-284.
[54]
Zhang, J.; Ding, L.; Wang, B.; Ren, G.; Sun, A.; Deng, C.; Wei, X.; Mani, S.; Wang, Z.; Dou, W. Notoginsenoside R1 attenuates experimental inflammatory bowel disease via pregnane X receptor activation. J. Pharmacol. Exp. Ther., 2015, 352, 315-324.
[55]
Moore, L.B.; Maglich, J.M.; McKee, D.D.; Wisely, B.; Willson, T.M.; Kliewer, S.A.; Lambert, M.H.; Moore, J.T.; Pregnane, X. Receptor (PXR), Constitutive Androstane Receptor (CAR), and Benzoate X Receptor (BXR) define three pharmacologically distinct classes of nuclear receptors. Mol. Endocrinol., 2002, 16, 977-986.
[56]
Carazo, A.; Dusek, J.; Holas, O.; Skoda, J.; Hyrsova, L.; Smutny, T.; Soukup, T.; Dosedel, M.; Pávek, P. Teriflunomide is an indirect human Constitutive Androstane Receptor (CAR) activator interacting with Epidermal Growth Factor (EGF) signaling. Front. Pharmacol., 2018, 9, 993-1006.
[57]
Knebel, C.; Neeb, J.; Zahn, E.; Schmidt, F.; Carazo, A.; Holas, O.; Pavek, P.; Püschel, G.P.; Zanger, U.M.; Süssmuth, R.; Lampen, A.; Marx-Stoelting, P.; Braeuning, A. Unexpected effects of propiconazole, tebuconazole, and their mixture on the receptors CAR and PXR in human liver cells. Toxicol. Sci., 2018, 163, 170-181.
[58]
Benedict, W.F.; Considine, N.; Nebert, D.W. Genetic differences in aryl hydrocarbon hydroxylase induction and benzo(a)pyrene-produced tumorigenesis in the mouse. Mol. Pharmacol., 1973, 9, 266-277.
[59]
Poland, A.; Glover, E.; Kende, A.S. Stereospecific, high affinity binding of 2,3,7,8-tetrachlorodibenzo-p-dioxin by hepatic cytosol. Evidence that the binding species is receptor for induction of aryl hydrocarbon hydroxylase. J. Biol. Chem., 1976, 251, 4936-4946.
[60]
Hankinson, O. The aryl hydrocarbon receptor complex. Annu. Rev. Pharmacol. Toxicol., 1995, 35, 307-340.
[61]
Diaz, D.; Fabre, I.; Daujat, M.; Saint Aubert, B.; Bories, P.; Michel, H.; Maurel, P. Omeprazole is an aryl hydrocarbon-like inducer of human hepatic cytochrome P450. Gastroenterology, 1990, 99, 737-747.
[62]
Fuhr, U. Induction of drug metaboliing enzymes: Pharmacokinetic and toxicological consequences in humans. Clin. Pharmacokinet., 2000, 38, 493-504.
[63]
Nguyen, N.T.; Nakahama, T.; Nguyen, C.H.; Tran, T.T.; Le, V.S.; Chu, H.H.; Kishimoto, T. Aryl hydrocarbon receptor antagonism and its role in rheumatoid arthritis. J. Exp. Pharmacol., 2015, 7, 29-35.
[64]
Issemann, I.; Green, S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature, 1990, 347, 645-650.
[65]
Forman, B.M.; Chen, J.; Evans, R.M. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proc. Natl. Acad. Sci. USA, 1997, 94, 4312-4317.
[66]
Schmiedlin-Ren, P.; Thummel, K.E.; Fisher, J.M.; Paine, M.F.; Lown, K.S.; Watkins, P.B. Expression of enzymatically active CYP3A4 by Caco-2 cells grown on extracellular matrix-coated permeable supports in the presence of 1alpha,25-dihydroxyvitamin D3. Mol. Pharmacol., 1997, 51, 741-754.
[67]
Drocourt, L.; Ourlin, J.C.; Pascussi, J.M.; Maurel, P.; Vilarem, M.J. Expression of CYP3A4, CYP2B6, and CYP2C9 is regulated by the vitamin D receptor pathway in primary human hepatocytes. J. Biol. Chem., 2002, 277, 25125-25132.
[68]
Chen, K.S.; DeLuca, H.F. Cloning of the human 1 alpha,25-dihydroxyvitamin D-3 24-hydroxylase gene promoter and identification of two vitamin D-responsive elements. Biochim. Biophys. Acta, 1995, 1263, 1-9.
[69]
Goodwin, B.; Jones, S.A.; Price, R.R.; Watson, M.A.; McKee, D.D.; Moore, L.B.; Galardi, C.; Wilson, J.G.; Lewis, M.C.; Roth, M.E.; Maloney, P.R.; Willson, T.M.; Kliewer, S.A. A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. Mol. Cell, 2000, 6, 517-526.
[70]
Janowski, B.A.; Willy, P.J.; Devi, T.R.; Falck, J.R.; Mangelsdorf, D.J. An oxysterol signalling pathway mediated by the nuclear receptor LXR alpha. Nature, 1996, 383, 728-731.
[71]
Forman, B.M.; Goode, E.; Chen, J.; Oro, A.E.; Bradley, D.J.; Perlmann, T.; Noonan, D.J.; Burka, L.T.; McMorris, T.; Lamph, W.W.; Evans, R.M.; Weinberger, C. Identification of a nuclear receptor that is activated by farnesol metabolites. Cell, 1995, 81, 687-693.
[72]
Cheung, C.; Akiyama, T.E.; Kudo, G.; Gonzalez, F.J. Hepatic expression of cytochrome P450s in hepatocyte nuclear factor 1-alpha (HNF1alpha)-deficient mice. Biochem. Pharmacol., 2003, 66, 2011-2020.
[73]
Jover, R.; Bort, R.; Gomez-Lechon, M.J.; Castell, J.V. Cytochrome P450 regulation by hepatocyte nuclear factor 4 in human hepatocytes: a study using adenovirus- mediated antisense targeting. Hepatology, 2001, 33, 668-675.
[74]
Corchero, J.; Granvil, C.P.; Akiyama, T.E.; Hayhurst, G.P.; Pimprale, S.; Feigenbaum, L.; Idle, J.R.; Gonzalez, F.J. The CYP2D6 humanized mouse: effect of the human CYP2D6 transgene and HNF4 alpha on the disposition of debrisoquine in the mouse. Mol. Pharmacol., 2001, 60, 1260-1267.
[75]
Jover, R.; Bort, R.; Gómez-Lechón, M.J.; Castell, J.V. Re-expression of C/EBP alpha induces CYP2B6, CYP2C9 and CYP2D6 genes in HepG2 cells. FEBS Lett., 1998, 431, 227-230.
[76]
Teschke, R.; Wolff, A.; Frenzel, C.; Schwarzenboeck, A.; Schulze, J.; Eickhoff, A. Drug and herb induced liver injury: Council for international organizations of medical sciences scale for causality assessment. World J. Hepatol., 2014, 6, 17-32.
[77]
Aithal, G.P.; Watkins, P.B.; Andrade, R.J.; Larrey, D.; Molokhia, M.; Takikawa, H.; Hunt, C.M.; Wilke, R.A.; Avigan, M.; Kaplowitz, N.; Bjornsson, E.; Daly, A.K. Case definition and phenotype standardization in drug-induced liver injury. Clin. Pharmacol. Ther., 2011, 89, 806-815.
[78]
Teschke, R.; Schmidt-Taenzer, W.; Wolff, A. Spontaneous reports of assumed herbal hepatotoxicity by black cohosh: is the liver-unspecific Naranjo scale precise enough to ascertain causality? Pharmacoepidemiol. Drug Saf., 2011, 20, 567-582.
[79]
Kim, T.Y.; Kim, D. Acute-on-chronic liver failure. Clin. Mol. Hepatol., 2013, 19, 349-359.
[80]
Larson, A.M. Diagnosis and management of acute liver failure. Curr. Opin. Gastroenterol., 2010, 26, 214-221.
[81]
Larson, A.M.; Polson, J.; Fontana, R.J.; Davern, T.J.; Lalani, E.; Hynan, L.S.; Reisch, J.S.; Schiødt, F.V.; Ostapowicz, G.; Shakil, A.O.; Lee, W.M. Acute Liver Failure Study Group. Acetaminophen-induced acute liver failure: Results of a United States multicenter, prospective study. Hepatology, 2005, 42, 1364-1372.
[82]
Krishna, Y.R.; Mittal, V.; Grewal, P.; Fiel, M.I.; Schiano, T. Acute liver failure caused by ‘fat burners’ and dietary supplements: A case report and literature and literature review. Can. J. Gastroenterol., 2011, 25, 157-160.
[83]
Gunawan, B.; Kaplowitz, N. Clinical perspectives on xenobiotic induced hepatoxicity. Drug Metab. Rev., 2004, 36, 301-312.
[84]
Stewart, M.J.; Steenkamp, V. Pyrrolizidine poisoning: A neglected area in human toxicology. Ther. Drug Monit., 2001, 23, 698-708.
[85]
Pittler, M.H.; Ernst, E. Systematic review: Hepatotoxic events associated with herbal medicinal products. Aliment. Pharmacol. Ther., 2003, 18, 451-471.
[86]
Schiano, T.D. Hepatotoxicity and complementary and alternative medicines. Clin. Liver Dis., 2003, 7, 453-473.
[87]
Stedman, C. Herbal hepatotoxicity. Semin. Liver Dis., 2002, 22, 195-206.
[88]
Teschke, R.; Bahre, R. Severe hepatotoxicity by Indian Ayurvedic herbal products: A structured causality assessment. Ann. Hepatol., 2009, 8, 258-266.
[89]
Dantuluri, S.; North-Lewis, P.; Karthik, S.V. Gotu Kola induced hepatotoxicity in a child- need for caution with alternative remedies. Dig. Liver Dis., 2011, 43, 500-504.
[90]
Jorge, O.A.; Jorge, A.D. Hepatotoxicity associated with the ingestion of Centella asiatica. Rev. Esp. Enferm. Dig., 2005, 97, 115-124.
[91]
Fleig, W.W.; Morgan, M.Y.; Holzer, M.A. European multicenter study group. The ayurvedic drug Liv.52 in patients with alcoholic cirrhosis. Results of a prospective, randomized, double-blind, placebo-controlled clinical trial. J. Hepatol., 1997, 126, 127-132.
[92]
Modi, A.A.; Wright, E.C.; Leonard, B.S. Complementary and Alternative Medicine for the treatment of hepatitis B and C: A review. Antivir. Ther., 2007, 12, 285-295.
[93]
Yuen, M.F.; Tam, S.; Fung, J.; Wong, D.K.; Wong, B.C.; Lai, C.L. Traditional Chinese Medicine causing hepatotoxicity in patients with chronic hepatitis B infection: A 1-year prospective study. Aliment. Pharmacol. Ther., 2006, 24, 1179-1186.
[94]
Lee, C.H.; Wang, J.D.; Chen, P.C. Risk of liver injury associated with Chinese herbal products containing Radix bupleuri in 639,779 patients with hepatitis B virus infection. PLoS One, 2011, 6, e16064.
[95]
Estes, J.D.; Stolpman, D.; Olyaei, A.; Corless, C.L.; Ham, J.M.; Schwartz, J.M.; Orloff, S.L. High prevalence of potentially hepatotoxic herbal supplement use in patients with fulminant hepatic failure. Arch. Surg., 2003, 138, 852-858.
[96]
Petry, J.J. Garlic and postoperative bleeding. Plast. Reconstr. Surg., 1995, 96, 483-484.
[97]
Sunter, W.H. Warfarin and garlic. Pharm. J., 1991, 246, 772-775.
[98]
Evans, V. Herbs and the brain: Friend or foe? The effects of ginkgo and garlic on warfarin use. J. Neurosci. Nurs., 2000, 32, 229-232.
[99]
Galluzzi, S.; Zanetti, O.; Binetti, G.; Trabucchi, M.; Frisoni, G.B. Coma in a patient with Alzheimer’s disease taking low dose trazodone and Ginkgo biloba. J. Neurol. Neurosurg. Psychiatry, 2000, 68, 679-680.
[100]
Jones, B.D.; Runikis, A.M. Interaction of ginseng with phenelzine. J. Clin. Psychopharmacol., 1987, 7, 201-202.
[101]
Piscitelli, S.C.; Burstein, A.H.; Welden, N.; Gallicano, K.D.; Falloon, J. The effect of garlic supplements on the pharmacokinetics of saquinavir. Clin. Infect. Dis., 2002, 34, 234-238.
[102]
Sitprija, S.; Plengvidhya, C.; Kangkaya, V.; Bhuvapanich, S.; Tunkayoon, M. Garlic and diabetes mellitus phase II clinical trial. J. Med. Assoc. Thai., 1987, 70, 223-227.
[103]
Gorski, J.C.; Jones, D.R.; Hamman, M.A.; Wrighton, S.A.; Hall, S.D. Biotransformation of alprazolam by members of the human cytochrome P4503A subfamily. Xenobiotica, 1999, 29, 931-944.
[104]
Piscitelli, S.C.; Formentini, E.; Burstein, A.H.; Alfaro, R.; Jagannatha, S.; Falloon, J. Effect of milk thistle on the pharmacokinetics of indinavir in healthy volunteers. Pharmacotherapy, 2002, 22, 551-556.
[105]
Mauro, V.F.; Mauro, L.S.; Kleshinski, J.F. Khuder, S.A.; Wang, Y.; Erhardt, P.W. Impact of Ginkgo biloba on the pharmacokinetics of digoxin. Am. J. Ther., 2003, 10, 247-251.
[106]
Hu, Z.; Yang, X.; Ho, P.C.; Chan, S.Y.; Heng, P.W.; Chan, E.; Duan, W.; Koh, H.L.; Zhou, S. Herb-drug interactions: A literature review. Drugs, 2005, 65, 1239-1282.
[107]
Izzo, A.A. Interactions between Herbs and conventional drugs: Overview of the clinical data. Med. Princ. Pract., 2012, 21, 404-428.
[108]
Tsukamoto, S; Aburatani, M; Ohta, T. Isolation of CYP3A4 inhibitors
from the black cohosh (Cimicifuga racemosa). eCAM, 2005, 2, 223-226.
[109]
Budzinski, J.W.; Foster, B.C.; Vandenhoek, S.; Arnason, J.T. An in vitro evaluation of human cytochrome P450 3A4 inhibition by selected commercial herbal extracts and tinctures. Phytomedicine, 2000, 7, 273-282.
[110]
Toselli, F.; Matthiasv, A.; Gillam, E.M.J. Echinacea metabolism and drug interactions: The case for standardization of a complementary medicine. Life Sci., 2009, 85, 97-106.
[111]
Choi, H.A.; Kim, M-R.; Park, K.A.; Hong, J. Interaction of over-the-Counter Drugs with Curcumin: Influence on Stability and Bioactivities in Intestinal Cells. J. Agric. Food Chem., 2012, 60, 10578-10584.
[112]
Chen, X-W.; Sneed, K.B.; Pan, S-Y.; Cao, C.; Kanwar, J.R.; Chew, H.; Zhou, S-F. Herb-drug interactions and mechanistic and clinical considerations. Curr. Drug Metab., 2012, 13, 640-651.
[113]
Meng, Q.; Liu, K. Pharmacokinetic interactions between herbal medicines and prescribed drugs: Focus on drug metabolic enzymes and transporters. Curr. Drug Metab., 2014, 15, 791-707.
[114]
Darwich, A.S.; Neuhoff, S.; Jamei, M.; Rostami-Hodjegan, A. Interplay of metabolism and transport in determining oral drug absorption and gut wall metabolism: A simulation assessment using the “Advanced Dissolution, Absorption, Metabolism (ADAM)” model. Curr. Drug Metab., 2010, 11, 716-729.
[115]
Choi, J.G.; Eom, S.M.; Kim, J.; Kim, S.H.; Huh, E.; Kim, H.; Lee, Y.; Lee, H.; Oh, M.S. A Comprehensive review of recent studies on herb-drug interaction: A focus on pharmacodynamic interaction. J. Altern. Complement. Med. NYN, 2016, 22, 262-279.
[116]
Reeta, K.H.; Mehla, J.; Pahuja, M.; Gupta, Y.K. Pharmacokinetic and pharmacodynamic interactions of valproate, phenytoin, phenobarbitone and carbamazepine with curcumin in experimental models of epilepsy in rats. Pharmacol. Biochem. Behav., 2011, 99, 399-407.
[117]
Zhou, S.; Gao, Y.; Jiang, W.; Huang, M.; Xu, A.; Paxton, J.W. Interactions of herbs with cytochrome P450. Drug Metab. Rev., 2003, 35, 35-98.
[118]
Fasinu, P.S.; Bouic, P.J.; Rosenkranz, B. An overview of the evidence and mechanisms of herb-drug interactions. Front. Pharmacol., 2012, 3, 69-73.
[119]
Posadzki, P.; Watson, L.; Ernst, E. Herb-drug interactions: An overview of systematic reviews. Br. J. Clin. Pharmacol., 2013, 75, 603-618.
[120]
Nowack, R. Review article: Cytochrome P450 enzyme, and transport protein mediated herb-drug interactions in renal transplant patients: Grapefruit juice, St John’s Wort - and beyond! Nephrology, 2008, 13, 337-347.
[121]
Yang, S.Y.; Juang, S.H.; Tsai, S.Y.; Chao, P.D.; Hou, Y.C.St. John’s wort significantly increased the systemic exposure and toxicity of methotrexate in rats. Toxicol. Appl. Pharmacol., 2012, 263, 39-43.
[122]
Lin, K.; Lin, A.N.; Linn, S.; Hlaing, P.P.; Vasudev, V.; Reddy, M. Ginseng-related drug-induced liver injury. Case Rep. Gastroenterol., 2018, 12, 439-446.
[123]
Danan, G.; Teschke, R. Drug-induced liver injury: Why is the Roussel Uclaf Causality Assessment Method (RUCAM) still used 25 years after its launch? Drug Saf., 2018, 41(8), 735-743.
[124]
Teschke, R.; Schulze, J.; Eickhoff, A.; Danan, G. Drug induced liver injury: Can biomarkers assist RUCAM in causality assessment? Int. J. Mol. Sci., 2017, 18, E803.
